ArticleBMC infectious diseases2021
Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Therapeutic strategies for multi-resistantJAC-antimicrobial resistance · 2026Review
- Comparative Analysis of Antimicrobial Resistance in Male Uropathogens Before and After the COVID-19 Pandemic: A Single-Center Study from Romania.Medicina (Kaunas, Lithuania) · 2026Article
- Carbapenem-resistantbioRxiv : the preprint server for biology · 2026Article
- Antimicrobial resistance patterns in UTIs in male patients with associated kidney stone disease: a descriptive study.Journal of medicine and life · 2026Observational
- Assessment of Factors Contributing to Multidrug Resistance in Urinary Tract Infections: Focus on Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2025Article
- Metatranscriptomics-based metabolic modeling of patient-specific urinary microbiome during infection.NPJ biofilms and microbiomes · 2025Article
- Epidemiological Trends of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Clinical and Economic Outcomes Associated with Complicated Urinary Tract Infections Caused by Carbapenem-resistantInfection & chemotherapy · 2025Article
- The Clinical Implications of Inappropriate Therapy in Community-Onset Urinary Tract Infections and the Development of a Bayesian Hierarchical Weighted-Incidence Syndromic Combination Antibiogram.Antibiotics (Basel, Switzerland) · 2025Article
- Nonenteric Pathogens in Urinary Tract Infections: Epidemiology and Resistance Patterns in Albania.Global health, epidemiology and genomics · 2025Article
- The incidence, clinical features and outcome of urinary tract infections in geriatric patients: A prospective longitudinal study.IJID regions · 2024Article
- Role of Ceftazidime-Avibactam in Urinary Tract Infections Caused by Carbapenem-Resistant Enterobacterales.Cureus · 2024Article
- A novel machine-learning aided platform for rapid detection of urine ESBLs and carbapenemases: URECA-LAMP.Journal of clinical microbiology · 2024Article
- Urinary Tract Infections with Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Occurrence of Imipenem-Resistant Uropathogenic Escherichia coli in Pregnant Women: An Insight into Their Virulence Profile and Clonal Structure.Current microbiology · 2024Article
- Epidemiology and Antimicrobial Resistance Patterns of Urinary Tract Infections: A Cross-Sectional Study from Southwestern Saudi Arabia.Medicina (Kaunas, Lithuania) · 2023Article
- Clinical characteristics, risk factors and outcomes of Klebsiella pneumoniae pneumonia developing secondary Klebsiella pneumoniae bloodstream infection.BMC pulmonary medicine · 2023Observational
- Comprehensive assessment of holding urine as a behavioral risk factor for UTI in women and reasons for delayed voiding.BMC infectious diseases · 2022Article
- The Economic Impact of Carbapenem Resistant-Non Lactose Fermenter andAntibiotics (Basel, Switzerland) · 2022Article
- Urinary Tract Infections in Elderly Patients: A 10-Year Study on Their Epidemiology and Antibiotic Resistance Based on the WHO Access, Watch, Reserve (AWaRe) Classification.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUrinary tract infections (UTIs) are the most common infections caused by Gram-negative bacteria and represent a major healthcare burden. Carbapenem-resistant (CR) strains of Enterobacterales and non-lactose fermenting pathogens further complicate treatment approaches.
methodsWe conducted a retrospective analysis of the US Premier Healthcare Database (2014-2019) in hospitalised adults with a UTI to estimate the healthcare burden of Gram-negative CR UTIs among patients with or without concurrent bacteraemia.
resultsAmong the 47,496 patients with UTI analysed, CR infections were present in 2076 (4.4%). Bacteraemia was present in 24.5% of all UTI patients, and 1.7% of these were caused by a CR pathogen. The most frequent CR pathogens were Pseudomonas aeruginosa (49.4%) and Klebsiella pneumoniae (14.2%). Patients with CR infections had a significantly longer hospital length of stay (LOS) (median [range] 8 [5-12] days vs 6 [4-10] days, P < 0.001), were less likely to be discharged home (38.4% vs 51.0%, P < 0.001), had a higher readmission rate (22.6% vs 13.5%, P < 0.001), and had greater LOS-associated charges (mean US$ 91,752 vs US$ 66,011, P < 0.001) than patients with carbapenem-susceptible (CS) infections, respectively. The impact of CR pathogens was greater in patients with bacteraemia (or urosepsis) and these CR urosepsis patients had a significantly higher rate of mortality than those with CS urosepsis (10.5% vs 6.0%, P < 0.001).
conclusionsAmong hospitalised patients with UTIs, the presence of a CR organism and bacteraemia increased the burden of disease, with worse outcomes and higher hospitalisation charges than disease associated with CS pathogens and those without bacteraemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.